Abbott Laboratories (ABT) Net Income towards Common Stockholders (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Net Income towards Common Stockholders data on file, last reported at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 18.72% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $6.3 billion (down 53.52% YoY), and the FY2025 full-year result was $6.5 billion, down 51.32% from the prior year.
• Net Income towards Common Stockholders declined to $1.1 billion in Q1 2026, from $1.8 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $9.2 billion in Q4 2024 to a low of $1.0 billion in Q4 2022.
• A 5-year average of $2.0 billion and a median of $1.4 billion in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 478.98% in 2024 and tumbled 80.76% in 2025, its largest moves.
• Tracing ABT's Net Income towards Common Stockholders over 5 years: stood at $1.0 billion in 2022, then soared by 54.31% to $1.6 billion in 2023, then jumped by 478.98% to $9.2 billion in 2024, then plunged by 80.76% to $1.8 billion in 2025, then tumbled by 39.36% to $1.1 billion in 2026.
• Business Quant data shows ABT's Net Income towards Common Stockholders at $1.1 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.6 billion in Q3 2025.